

Author(s): Aken Desai, Michael Mathis, 2008

License: Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution – Share Alike 3.0**

License: <http://creativecommons.org/licenses/by-sa/3.0/>

We have reviewed this material in accordance with U.S. Copyright Law **and have tried to maximize your ability to use, share, and adapt it.**

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

Student works are presented **as is** and may be an interpretation of faculty members' lectures or assignments. These student works are **not a product of faculty members**. Faculty do not guarantee the accuracy of student work nor endorse them in any way.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

Classification of Immune Mediated Tissue Injury

Tuesday, February 19, 2008
10:00 AM

- Type I: Anaphylactic Type
 - Allergen binding to mast cell to cause degranulation
 - Prototype disorders
 - Allergic rhinitis
 - Asthma
 - Anaphylaxis (insect venom)
 - Immune mechanism
 - IgE-Mast cell binding
 - Vascular permeability
 - Eosinophils
 - Clinical
 - Result of exposure to environmental allergens in genetically susceptible individuals
 - Genetics not clearly defined, but association exists
 - Atopy: genetic predisposition for developing IgE responses to many antigens
 - Local or systemic symptoms
 - Most common form - allergic rhinitis
 - Certain types of asthma
 - Atopic dermatitis (eczema)
 - GI food allergies
 - Allergens: pollens, molds, house dust mites, animal dander
 - Pathophysiology
 - Antigen presented by APC to Th cell --> IL-4 activation of B cell
 - IgE antibodies secreted by B cell
 - IgE antibodies bind to Fc receptors on mast cells
 - Antigen binds to IgE on mast cells
 - Degranulation of mast cell releases cytokines
 - IL-4,5,6 stimulates B cells
 - IL-3,4 stimulates GM-CSF, TNF- α , IL-8/0, inflammatory cell activation
 - Mediators have variety of effects
 - Increase vascular permeability
 - Constrict airways
 - Cell infiltration
 - Asthma, eczema, hay fever
 - Feedback effects on immune system
 - Effects of mediators
 - Histamine --> vascular permeability, vasodilation of post-capillary venule, smooth muscle contraction
 - Chemotactic factors
 - Cytokines
 - Lipid mediators
 - Arachidonic acid metabolites: LTC₄, D₄, E₄ --> smooth muscle contraction; prostaglandins --> vasodilation
 - PAF - platelet activating factor
 - Acetylated glycerol ether phosphocholine --> activates phagocytic cells, smooth muscle contraction
 - Eosinophils
 - Normal levels: 2 to 3% of total WBCs
 - Type 1 response: up to 10%

- Secretory products
 - NADPH oxidase derived oxidants
 - Prostaglandins and leukotrienes (LTC4)
 - Major basic protein: cytotoxic
 - Cytokines
 - Others
 - Symptoms depends on tgt organ
 - Skin
 - Gross: swelling, wheal and flare
 - ◆ Early: preformed mediators
 - ◆ Late: synthesized mediators
 - LM: edema, eosinophils
 - EM: edema, endothelial cell gaps
 - Mucous and serous glands: increased secretion
 - Bronchial and GI smooth muscle contraction
 - Threapeutics
 - Avoid antigen
 - Mediator antagonists
 - Anti-histamines: receptor antagonist
 - Leukotriene inhibitors: lipase inhibitors, receptor antagonists
 - Fxnl: sympathetic stimulatants (EPI)
 - Inhibit mast cell degranulation: cromolyn
 - Non-specific anti-inflammatory agents: corticosteroids
 - Immunotherapy: "allergy shots"
 - Diagnosis
 - Skin tests: swell, wheal, flare (w/in mins) --> Type I hypersensitivity
 - RAST: bead w/ Ag + pt's serum + antihuman IgE --> if fluorescent --> allergic
 - RIST: bead + anti-human IgE + serum --> how much IgE
- Type II, Cytotoxic type
 - Involves binding of IgG to tgt cell and cytotoxic action/complement activation
 - Prototype disorders
 - Hemolytic rxns
 - Goodpastures syndrome
 - Myasthenia gravis
 - Grave's disease (hyperthyroidism)
 - Immune Mechanisms
 - IgG
 - Complement
 - Phagocytic cells
 - ADCC
 - Pathophysiology
 - Binding of antibody w/ cell membrane or tissue antigens
 - RBC membrane antigens - hemolytic anemias
 - Mother is Rh-
 - First baby is Rh+
 - Mother develops anti-Rh+ IgG
 - 2nd child is Rh+
 - IgG crosses placenta
 - Binds to RBC of fetus --> hemolysis
 - Treat by blocking sensitization of mother anti-D Ig w/in 72 hrs of first birth
 - Platelet antigens - thrombocytopenia cell membrane - petechiae
 - Basement membrane - goodpasture's syndrome (kidney, lung)
 - Mechanisms
 - Opsonin dependent phagocytosis

- Complement dependent Ab lysis
- Ab-dependent cell cytotoxicity
- Examples
 - Goodpasture's: antigen is basement membrane of kidney and lung
 - Dermatitis herpetiformis: basement membrane reticulin
 - Bullous pemphigoid: epidermis basement membrane
 - Pemphigus vulgaris: epidermis keratinocyte membrane
- N'phil, frustrated phagocytosis, extracellular enzyme release
- Goodpasture's
 - Hemoptysis, pulmonary infiltrates, renal failure, anemia
 - Pathology
 - Circulating anti-GBM antibodies
 - LM: n'phils, hemorrhage
 - Immunofluorescence: Ig and complement deposition; linear
 - ◆ Linear antigen deposition --> Ab + complement deposition --> linear secondary anti-human Ab to IgG or complement contain fluorescent marker
 - EM: no electron dense deposits
 - Antibody binds to GBM --> complement --> C3b deposition + C3a/C5a --> PMN recruitment --> proteases + ROS --> tissue injury
 - Lung: hemorrhage, hemoptysis, alveolar infiltrates
 - Kidney: proteinuria, hematuria, renal failure
- Antibody binding to cell receptor (Type V rxns)
 - Grave's disease: IgG binds to TSH-R and stimulates cell to make T3/T4
 - Myasthenia Gravis: Ab to Ach-R at synapse blocks neuromuscular transmission --> muscle weakness
- Type III, Immune Complex Disease
 - Antibody binds to antigen and deposits on tissues
 - Prototype disorders
 - Post-strep glomerulonephritis
 - Vasculitis: polyarteritis nodosa
 - Immune mechanisms
 - Ab-Ag rxns
 - Complement
 - Neutrophils
 - Fibrin, hemorrhage
 - Pathophysiology
 - Ag-Ab complex deposits in tissues
 - Complement activation via IgG/IgM --> C5a
 - Monocyte/mphage activation --> cytokines
 - N'phil influx
 - Phagocytosis of immune complexes
 - Release of ROS and lysosomal enzymes
 - Tissue Injury (fibrinoid necrosis, hemorrhage, n'phils, Ab+complement deposition)
 - LM: n'phils, hemorrhage, edema
 - EM: electron dense deposits
 - Granular immunofluorescence
 - Systemic Immune Complex Disease
 - Foreign antigen injected IV
 - Immune response w/ Ab prod (IgM, IgG)
 - Circulating immune complexes formed
 - Tissue deposition w/ complement fixation
 - Arteritis/glomerulonephritis (w/ proteinuria)
 - Clinical
 - Depends on tgt organ and/or site of immune complex deposition

- Synovium - RA
 - Kidney - glomerulus
 - Post-strep glomerulonephritis --> granular immunofluorescence
 - Systemic lupus erythematosus
 - Blood vessel walls - vasculitis
 - Polyarteritis nodosa
 - Early transplant rejection
 - Lung - hypersensitivity pneumonitis
- Diagnosis
 - Skin tests for Type III rxns
 - Takes several hours to manifest b/c requires complement fixation
- Treatment
 - Elimination of antigen - transfusion rxns, hypersensitivity lung rxns to foreign antigens, certain drug rxns
 - Corticosteroid and immunosuppressive therapy (cytoxan, cyclosporin, anti-TNFs)
 - Plasmapheresis - filtration of plasma antibodies
- Type IV, Cell-Mediated (Delayed) Hypersensitivity
 - Antigen binding to T cells causes m'phage activation and release of inflammatory mediators
 - Prototype Disorders
 - Poison Ivy, epidermal
 - Eczema
 - Infiltration of lymphocytes and later macrophages, edema
 - 1st contact sensitizes --> creation of T memory cells
 - 2nd contact --> T memory cells --> Th cells --> m'phage activation --> dermatitis
 - Tuberculosis
 - Local hardening and swelling +/- fever
 - Infiltration of lymphocytes, monocytes and m'phages
 - Intradermal injection used diagnostically, tuberculin, mycobacterial and leishmanial antigens
 - Granulomatous
 - 4 wk rxn time
 - Hardening in skin or lung
 - Granuloma containing epithelioid cells, giant cells, m'phages; fibrosis +/- necrosis
 - Persistent Ag or Ag-Ab complexes in m'phages or non-immunological
 - Cytotoxic T-Cells
 - Immune Mechanisms
 - T-lymphocytes
 - Monocytes/macrophages
 - Sensitization phase
 - Hapten enters and is taken up by Langerhans' cells in skin
 - Migrates to lymph node
 - Germinal center forms --> T cells proliferate
 - Contact hypersensitivity
 - Hapten enters and is carried to circulation
 - Binds to langerhans cel
 - CD8, Th1 cells activated
 - Macrophage activated
 - Granulomatous Inflammatory Rxns
 - APC-Th1 interaction --> IL-2 --> T cell proliferation
 - IL-3,6, IFN- γ , TNF --> m'phage activation --> epithelioid cell --> TNF causes fusion to make giant cell
 - M'phages and lymphocytes surround antigen-antibody complexes to prevent spread
 - Skin Test takes 48-72 hours
- T-Cell Mediated Cytotoxicity

- Mechanisms
 - CD8+ T cell
 - Antigen expressed w/ class I MHC
 - IL-2 clonal expansion
 - Cytotoxic effector cell recognizes Ag+class I MHC
- Initiates programmed cell death
 - Perforins/cytolysins
 - Proteolytic enzymes: granzymes
 - FAS-induced apoptosis: CD8+ T cell:FAS ligand
 - Cytokines: IFN γ , TNF α / β